Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

NCT01068587 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

NCT01697163 ·Status: UNKNOWN

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

NCT03292133 ·Status: TERMINATED ·Phase: PHASE2

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT02206763 ·Status: TERMINATED ·Phase: PHASE1

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689 ·Status: RECRUITING ·Phase: PHASE2

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs

NCT06863818 ·Status: ACTIVE_NOT_RECRUITING

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185 ·Status: UNKNOWN ·Phase: PHASE2

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211 ·Status: COMPLETED

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

NCT00836160 ·Status: COMPLETED

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

NCT05768490 ·Status: RECRUITING ·Phase: PHASE3

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

NCT00633490 ·Status: UNKNOWN ·Phase: PHASE1

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium

NCT03761901 ·Status: COMPLETED

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

NCT02299765 ·Status: TERMINATED ·Phase: PHASE4

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

NCT03529084 ·Status: WITHDRAWN ·Phase: PHASE3

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

NCT06706713 ·Status: RECRUITING ·Phase: PHASE2

First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

NCT00339586 ·Status: UNKNOWN ·Phase: PHASE2

Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)

NCT01573702 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

NCT02616393 ·Status: COMPLETED ·Phase: PHASE2

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT06685718 ·Status: TERMINATED ·Phase: PHASE1

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

NCT05620914 ·Status: WITHDRAWN ·Phase: PHASE2

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

NCT05688605 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

NCT06221475 ·Status: COMPLETED ·Phase: PHASE1

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

NCT00579683 ·Status: COMPLETED